Comparative Pharmacology
Head-to-head clinical analysis: ROGAINE FOR WOMEN versus ROGAINE EXTRA STRENGTH FOR MEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROGAINE FOR WOMEN versus ROGAINE EXTRA STRENGTH FOR MEN.
ROGAINE (FOR WOMEN) vs ROGAINE EXTRA STRENGTH (FOR MEN)
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Minoxidil is a potassium channel opener. It causes vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arteriolar smooth muscle. This improves blood flow to hair follicles and prolongs the anagen phase of hair growth, possibly by increasing vascular endothelial growth factor (VEGF) and other growth factors.
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.
FDA-approved: Treatment of female androgenetic alopecia (female pattern hair loss) in women aged 19-49 years with mild to moderate hair lossOff-label: Treatment of male pattern baldness (off-label for women if used for this purpose), alopecia areata, and other forms of hair thinning
Treatment of androgenetic alopecia (male pattern baldness) in men
Apply 1 mL of 2% minoxidil solution topically to the scalp twice daily (total 2 mL per day).
1 mL of 5% minoxidil solution applied topically to the scalp twice daily.
None Documented
None Documented
The terminal elimination half-life of minoxidil is approximately 4.2 hours (range 2–7 hours) following topical application, but the pharmacodynamic half-life (duration of drug presence in the skin and hair follicle) is longer, estimated at 24 hours. For oral minoxidil, the terminal half-life averages 4.5 hours (range 3–7 hours).
Terminal elimination half-life is approximately 4.2 hours (range 3.5–5.0 hours) in healthy adults. Clinical context: Maintains steady-state concentrations with twice-daily topical application without significant accumulation.
Minoxidil is primarily metabolized in the liver via glucuronidation to minoxidil glucuronide, which is inactive. Minor metabolism via sulfation may occur. The metabolism is mediated by UDP-glucuronosyltransferases (UGTs).
Minoxidil is primarily metabolized by conjugation with glucuronic acid at the N-oxide position in the liver. CYP450 enzymes are minimally involved.
Renal excretion of unchanged minoxidil and its glucuronide conjugates accounts for approximately 95% of the absorbed dose; about 5% is eliminated unchanged in feces via biliary excretion.
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination. Fecal excretion is minimal (<3%).
Minoxidil is approximately 20% bound to serum proteins, primarily albumin, with negligible binding to alpha-1-acid glycoprotein.
Approximately 20% bound to plasma proteins (primarily albumin).
The apparent volume of distribution for minoxidil is 3.5 L/kg (range 2.5–4.5 L/kg), indicating extensive extravascular distribution and tissue binding, particularly to vascular smooth muscle.
Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into total body water and tissues.
Absolute bioavailability of topical minoxidil is approximately 1.5% (range 0.3–3.2%) of the applied dose, due to low percutaneous absorption and extensive first-pass metabolism in the skin. Oral minoxidil has an absolute bioavailability of 90%.
Topical: systemic bioavailability is low (approximately 1.4% of applied dose) due to poor percutaneous absorption. Oral: approximately 50% (not indicated for this formulation).
No dosage adjustment required for renal impairment.
No dosage adjustment required for renal impairment; not systemically absorbed in significant amounts.
No dosage adjustment required for hepatic impairment.
No dosage adjustment required for hepatic impairment; not systemically absorbed in significant amounts.
Safety and efficacy not established; use is not recommended.
Safety and effectiveness in pediatric patients under 18 years have not been established.
No specific dose adjustment; use with caution due to potential increased sensitivity.
No specific dosage adjustment; use with caution due to potential for increased systemic absorption from thinner skin.
None for topical minoxidil (Rogaine for Women). Oral minoxidil (not this formulation) carries a boxed warning for adverse cardiovascular effects.
No FDA boxed warning.
["Systemic absorption can cause cardiovascular effects such as tachycardia, fluid retention, and hypotension (rare with topical use)","May cause local skin reactions: irritation, redness, itching, or dryness","Potential for increased hair loss initially (shedding of telogen hairs) during first 2-6 weeks","Avoid contact with eyes, mucous membranes, and broken skin","Use caution in patients with underlying cardiovascular disease (angina, arrhythmias, heart failure)","Discontinue if systemic side effects occur or if no improvement after 6 months"]
["Cardiovascular risks such as tachycardia, fluid retention, and pericardial effusion with topical use are rare but possible.","May cause hypotension if accidentally ingested.","Avoid contact with eyes and broken skin.","Discontinue if scalp irritation occurs.","Use with caution in patients with hypertension or underlying cardiovascular disease."]
["Hypersensitivity to minoxidil or any component of the formulation","Use on broken, irritated, or sunburned scalp","Concomitant use with other topical agents that may increase absorption (e.g., corticosteroids, tretinoin)","Relative: Pregnancy and breastfeeding (minoxidil is pregnancy category C; use only if benefit outweighs risk)"]
["Hypersensitivity to minoxidil or any component of the formulation.","Concomitant use with other topical agents on the scalp."]
Data Pending Review
Data Pending Review
No clinically significant food interactions. Avoid excessive caffeine or stimulants as they may exacerbate anxiety or palpitations (rare systemic absorption).
No known food interactions.
Topical minoxidil (Rogaine for Women) has limited human pregnancy data. Animal studies show no teratogenic effects at systemic exposures up to 5 times the human topical dose. Systemic absorption is minimal (<1.5%) with recommended topical use, but it is classified as pregnancy category C. First trimester: theoretical risk, avoid use. Second and third trimesters: minimal known risk but use only if clearly needed.
Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the human dose. Human data are insufficient; risk is considered low but cannot be excluded. Use only if clearly needed during pregnancy. No specific trimester risks identified.
Minoxidil is excreted in human milk following oral administration; however, data after topical use are lacking. The milk-to-plasma ratio (M/P) is unknown for topical application. Due to potential for adverse effects in the nursing infant (e.g., hypotension), breastfeeding is not recommended during treatment.
Minoxidil is excreted in human milk following oral administration; however, following topical application, systemic absorption is minimal (1.4%). The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No dose adjustments are recommended based on pharmacokinetic changes in pregnancy, as systemic absorption is minimal. However, use during pregnancy is generally discouraged. If used, the standard dose (2% or 5% solution, 1 mL twice daily) should not be exceeded.
No dose adjustment is necessary. Pharmacokinetic changes in pregnancy (e.g., increased blood volume, altered skin perfusion) are not expected to significantly alter the minimal systemic absorption of topical minoxidil. Use standard dosing: 1 mL twice daily to the scalp.
Category C
Category C
Minoxidil 5% foam is first-line for female pattern hair loss (FPHL). Response requires 4-6 months of consistent use; counsel patients not to expect immediate results. Initial shedding may occur in first 2-6 weeks due to telogen effluvium; this is a positive sign of drug activity. Discontinue if scalp irritation or hypertrichosis develops. Avoid use on broken or sunburned skin. Apply to dry scalp, not to hair shaft.
Rogaine Extra Strength (5% minoxidil) is indicated for androgenetic alopecia in men. Onset of hair regrowth typically occurs after at least 4 months of twice-daily use; continued use is required to maintain effects. Discontinue if scalp irritation or unwanted facial hair growth occurs. Not effective for receding frontal hairline; primarily promotes vertex balding. May cause initial shedding of telogen hairs, which is a sign of efficacy.
Apply 1/2 capful of foam to dry scalp once daily, no need to rinse.Results take at least 4 months; continue use to maintain regrowth.Initial hair shedding is temporary and normal.Do not use if pregnant or breastfeeding.Avoid contact with eyes; if contact occurs, rinse with cool water.Wash hands after application.Do not use on other body parts.
Apply 1 mL directly to the scalp in the affected area twice daily, not more often.Wash hands thoroughly after each application.Do not apply to wet hair or within 24 hours of using other scalp treatments.Results may take 4 months or longer; continued use is necessary to maintain regrowth.Initial hair shedding is normal and indicates new hair growth.Avoid contact with eyes; if accidental contact occurs, rinse with cool water.